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Abstract. Conditioned medium (CM) derived from co- 
cultures of bovine aortic endothelial cells (BAECs) and 
bovine smooth muscle cells (BSMCs) contains trans- 
forming growth factor-fl (TGF-/3) formed via a plasmin- 
dependent activation of latent TGF-/3 (LTGFfl), which 
occurs in heterotypic but not in homotypic cultures 
(Sato,  Y., and D. B.  Rifkin.  1989. J.  Cell Biol.  107: 
1199-1205).  The TGF-fl formed is able to block the" 
migration of BSMCs or BAECs. We have found that 
the simultaneous addition to heterotypic culture medi- 
um of plasminogen and the atherogenic lipoprotein, 
lipoprotein (a) (Lp(a)),  which contains plasminogen- 
like kringles,  inhibits the activation of LTGF-/3 in a 
dose-dependent manner.  The inclusion of LDL in the 
culture medium did not show such an effect. Control 
experiments indicated that Lp(a) does not interfere 
with the basal level of cell migration,  the activity of 
exogenous added TGF-fl, the release of LTGF-fl  from 
cells, the activation of LTGF-fl  either by plasmin or by 
transient acidification,  or the activity of plasminogen 
activator.  The addition of Lp(a) to the culture medium 
decreased the amount of plasmin found in BAECs/ 
BSMCs cultures.  Similar results were obtained using 
CM derived from cocultures of human umbilical vein 
endothelial cells and human foreskin fibroblasts. These 
results suggest that Lp(a) can inhibit the activation of 
LTGF-/3 by competing with the binding of plasminogen 
to cell or matrix  surfaces.  Therefore, high plasma lev- 
els of Lp(a) might enhance smooth muscle cell migra- 
tion by decreasing the levels of the migration  inhibitor 
TGF-/3 thus contributing to generation of the athero- 
matous lesions. 
U'OPROTEIN (a) (Lp(a)) is an LDL-like lipoprotein whose 
increased concentration  in plasma is related to in- 
creased  risk  of atherosclerosis  (Scanu  and  Fless, 
1990).  In addition  to apolipoprotein B-100, Lp(a) contains 
a unique apolipoprotein called apolipoprotein  (a) which is 
disulfide  linked to the apolipoprotein B-100 (Fless et al., 
1986).  Recent studies  have revealed that apolipoprotein  (a) 
shares a remarkable structural homology with plasminogen, 
the zymogen form of the protease plasmin  (McLean et al., 
1987). Apolipoprotein (a) resembles plasminogen  as it con- 
tains one copy of the plasminogen  kringle-5 domain, a vari- 
able number of copies of the kringle-4 domain and a serine 
protease domain;  however little enzymatic activity has been 
detected associated with the purified  molecule (McLean et 
al., 1987; Utermann,  1989). Because of the presence of the 
large number of kringle domains that are responsible for the 
binding  of plasminogen  to fibrin,  matrix components,  and 
cell surfaces,  it has been suggested that Lp(a) competitively 
inhibits plasminogen  binding  to the endothelial  cell surface 
and,  therefore,  modulates fibrinolysis  (Miles et al.,  1989; 
Hajjar et al.,  1989). Lp(a) also attenuates  fibrin-dependent 
tissue-type plasminogen activator (tPA) activity through com- 
petitive inhibition  of the binding of plasminogen  and tPA to 
fibrin (Harpel et al., 1989; Loscalzo et al., 1990). However, 
the precise mechanism of Lp(a) atherogenicity  remains to be 
elucidated. 
The transforming growth factor-/3 (TGF-/3) family consists 
of a number of related,  but functionally  distinct,  proteins 
(Barnard  et al.,  1990; Roberts and Sporn,  1990).  The best 
characterized member of this  family  is TGF-/31. Although 
TGF-fll and the related molecules TGF-/32 and TGF-fl3 are 
produced and secreted by many normal and neoplastic cells 
in a latent high molecular weight form (LTGF-/3) that does 
not bind to the specific high affinity TGF-/3 receptors (Der- 
ynck et al., 1985; Barnard et al., 1990; Roberts and Sporn, 
1990). Although TGF-/31 was originally described as a mole- 
cule that induced anchorage  independent  growth of cells in 
soft agar, a hallmark of in vitro transformation  (De Larco 
and Todaro, 1978), TGF-~31 is now recognized to be a multi- 
functional cytokine with both growth promoting and growth 
inhibiting activities.  Some of the cell types whose growth is 
inhibited  by TGF-/3 are epithelial  cells,  lymphocytes, en- 
dothelial  cells  (ECs),  and  smooth  muscle  cells  (SMCs) 
(Moses et al., 1985; Kehrl et al.,  1986a,b; Heimark et al., 
1986; Owens et al.,  1988). 
A critical step in the regulation of TGF-/3 action is the acti- 
©  The Rockefeller University Press, 0021-9525/91/06/1439/7 $2.00 
The Journal of Cell Biology, Volume 113, Number 6, June 1991 1439-1445  1439 vation of the latent molecule. TGF-/~I is synthesized and re- 
leased as a 390-amino acid precursor polypeptide, which is 
both glycosylated and phosphorylated (Derynck et al., 1985, 
1986).  Cleavage in the carboxyl-terminal region yields the 
112-amino acid TGF-/$1 monomer. The 25-kD mature TGF-/3 
consists of two identical  monomer units linked by disulfide 
bonds (Roberts  and Sporn,  1990; Wakefield et al.,  1989). 
Latent transforming  growth factor-fl (LTGF-/3) contains one 
mature TGF-/3 molecule noncovalently  associated with the 
amino-terminal  portions of the propeptide dimer (Wakefield 
et al.,  1989).  (The propeptide dimer is often referred  to as 
the latency associated peptide or LAP). Acidification (pH 3) 
disrupts these noncovalent interactions  releasing TGF-/3 and 
is used as the standard method for the activation of LTGF-/$ 
(Barnard  et al., 1990; Roberts and Sporn, 1990). However, 
this is unlikely to be the physiological activation mechanism. 
Lyons et al. (1988, 1990) reported that proteases, specifically, 
plasmin  and cathepsin  D, can activate LTGF-/3 by cleavage 
within  the  amino-terminal  region  of LAE  Recently two 
papers described the activation  of LTGF-fl in cocultures of 
bovine ECs with either pericytes or SMCs (Antonelli-Orlidge 
et al.,  1989; Sato and Rifkin,  1989).  Both cell types were 
shown to produce LTGF-~ and the activation appears  to re- 
quire cell-cell contact.  The amount of LTGF-/3 activated is 
low, perhaps,  due to the self-regulation  of the system (Sato 
et al., 1990). Sato and Rifldn (1989) demonstrated that this 
activation requires cell-associated plasmin, produced by the 
conversion of plasminogen  to plasmin by plasminogen  acti- 
vator (PA) (Sato and Rifldn,  1989; Sato et al.,  1990).  The 
requirement for two different cell types does not appear to 
be related to activation of the PA-plasmin system as both cell 
types produce PA and both cell types contain PA receptors. 
The activation can be blocked by antibodies to PA and inhibi- 
tors of plasmin.  Thus, plasmin may be a relevant physiologi- 
cal activator of LTGF-B. 
The  requirement  for surface bound plasmin  for TGF-~ 
generation  suggested that Lp(a) might inhibit the activation 
of LTGF-~ in cocultures by competing for binding  of plas- 
minogen molecules.  We tested this assumption  by monitor- 
ing the effect of Lp(a) added to culture medium on the activa- 
tion of LTGF-/3 in cocultures.  Under these conditions  Lp(a) 
blocks the production of the negative regulator TGF-/~ pre- 
sumably by competing  for plasminogen  binding.  Moreover, 
the inclusion  of Lp(a)  in the culture medium abrogates  the 
migratory restraint normally observed when SMCs and ECs 
are in contact. Thus, under conditions of high levels of Lp(a) 
LTGF-/3 activation may be suppressed resulting in migration 
of SMCs from the media to the intima. 
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Materials and Methods 
Materials 
Lp(a) and LDL  were purified from fresh human plasma obtained from 
donors with elevated Lp(a) concentrations according to described methods 
(Harpel et al.,  1989).  Briefly,  Lp(a) and LDL purified from a  single in- 
dividual with an elevated Lp(a) concentration (80 mg/dl) according to de- 
scribed methods (Harpel et al.,  1989).  The purity of the preparation was 
documented by SDS-PAGE, followed by immunoblot analysis with mono- 
specific polyclonal antibodies against apo(a) and apo B-100, as well as by 
native 2-16% gradient polyacrylamide slab gel electrophoresis (Harpel et 
al., 1989).  The donor had a double-band Lp(a) phenotype, assessed by the 
method of Gaubatz (Gaubatz et al., 1990) and kindly performed by Dr. T. 
Parker, Cornell University Medical College, New York. The lower molecu- 
lar mass band 4 (Mr =  553 kD) was more intense than the higher molecu- 
lar mass band 8 (Mr =  742 kD). Purified lipoproteins were dialyzed against 
culture medium overnight at 4"C before being added to cells. The prepara- 
tion of plasminogen-depleted calf serum (CS) and the isolation of human 
plasminngen from fresh plasma were performed using lysine-Sepharose 
affinity chromatography (Robbins and Summaria, 1976). The plasminogen 
prepared in this manner was composed of>95 % Glu-plasminogen and <5 % 
Lys-forms as determined by a densitometric method following SDS-PAGE 
in the presence of 6 M urea (Suenson and Thorsen, 1981). Human ptasmin 
and  BSA were purchased from Sigma Chemical Co.  (St.  Louis,  MO). 
Recombinant human TGF-~I  was  a  generous gift from Genentec,  Inc. 
(South San Francisco, CA). Porcine TGP-~ and antibody to it (uTGF-B) 
were obtained from R & D Sys., Inc. (Minneapolis, MN). This t~TGF-/~  has 
previously been shown to neutralize porcine, human, and bovine TGF-~I 
(Keski-Oja et al., 1987; Sato and Rifkin, 1989).  The recombinant and por- 
cine TGF-fls were found to be equivalent in all assays.  Anti-bovine PA 
inhibitor-I (PAl-l) IgG (uPAI-1) was prepared from rabbit anti-bovine PAl-1 
serum which was a  generous gift from Dr.  David J.  Loskutoff (Scripps 
Clinic and Research Foundation, La Jolla, CA) using protein A-Sepharose 
(Pharmacia, Piscataway,  NJ). 
Cell Culture 
Bovine aortic endothelial cells (BAECs) and smooth muscle cells (BSMCs) 
were isolated and grown in alpha minimal essential medium (~MEM) con- 
taining 10%  CS or Dulbecco's modified essential medium (DMEM) con- 
taining  10%  CS,  respectively.  Human  umbilical  vein endothelial  cells 
(HUVECs), obtained from Dr. Richard I. Levin (Bellevue Hospital Center, 
New York, NY), and human foreskin fibroblasts (HFFs), were grown in ei- 
ther RPMI-1640 medium containing 20% FCS plus basic fibroblast growth 
factor (bFGF) (15 ng/mi) or DMEM containing 10%  FCS, respectively. 
Preparation of Conditioned Medium (CM) 
BAECs and BSMCs were detached from culture dishes with 0.25 % trypsin- 
0.1 mM EDTA. Cells were washed twice with serum-free c~MEM and were 
seeded in  35-mm dishes (8  cm  2)  at  a  density of 5  x  104 cells/cm  2 in 
t~MEM  containing  10%  plasminogen-depleted CS  plus  the  indicated 
amount of plasminngen. For coculture experiments, 3.2  x  105 BAECs and 
0.8  ×  105 BSMCs were seeded in the same 35-ram dishes in t~MEM con- 
taining 10% plasminogen-depleted CS plus the indicated amount of plas- 
minogen with and without Lp(a) or LDL. Since CS does not contain Lp(a) 
(Utermann, 1989),  the potential effects of Lp(a) in CS or FCS did not have 
to be considered. After a 2-h incubation at 37°C that permitted the cells 
to attach, the cultures were rinsed twice with PBS and incubated in 1 ml 
of serum-free aMEM containing 0.1% BSA (c~MEM-BSA) for an additional 
6 h to produce CM. The CM was centrifuged to remove cell debris, diluted 
to  1:4 with aMEM-BSA, and used in v~aund assays to measure BAEC 
migration.  For  wound assays  using  BSMCs,  CM  was  prepared  using 
DMEM containing 0.1% BSA. CM from HUVECs and/or HFFs were pre- 
pared as above except that RPMI-1640 medium plus 20%  plasminogen- 
depleted FCS was used for the initial 2-h incubation. 
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Wound assays for BAEC or BSMC migration  were carried out as described 
previously (Sato et al., 1990).  Briefly, a denuded area is made in a confluent  O 
monolayer using a razor blade. The cultures are incubated in the presence  ca 
of the additions to be tested for 24 h, the cells fixed, and the number of  .-  o 
cells that have migrated from the original edge counted (Sato and Rifidn,  ~  c 
1988).  TGF-/~ suppresses the migration of BAECs (Heimark et al.,  1986; 
Sato and Rifkin,  1988).  The number of cells which migrate is inversely  0~ 
proportional to the amount of TGF-/~ present. This assay can be used to de-  ~ 
tect concentrations of TGF-/3 as low as 10-20 pg/ml (Sato et ai., 1990).  In 
the case of BSMC, the incubation period was extended to 36 h because  .Q 
BSMCs migrated more slowly than BAECs. The data are presented as the  E 
number of cells that have migrated >125 #m from the original edge of the  Z 
wound in order to exclude those cells which moved across the origin before 
the TGF-B had an effect. This number represents the average obtained by 
counting the cells in six random fields from each of two replicate dishes. 
Assay of Cellular PA Activity 
Cellular PA activity was assayed as follows. After the initiation of incuba- 
tions in c~MEM-BSA,  the CM was aspirated at 0,  1, 3, and 6 h, the cells 
were washed three times with PBS, and the monolayer was extracted with 
0.5 % Triton X-100 in 0.1 M Tris-HC1, pH 8.1. The cell extracts were assayed 
for PA activity using the 125I-fibrin plate assay (Gross et al.,  1982). 
Assay of Cell-associated Plasmin Activity 
Trypsinized cells were replated into 24-well Linbro dishes (2 cm  2) and in- 
cubated for 2 h as described in Preparation of CM. Plasmin bound to the 
cell surface was then recovered and assayed according to the method of 
Stephens et al. (1989).  Briefly, after rinsing the cells with PBS three times, 
bound plasmin was eluted with 3 mM tranexamic acid in PBS. Plasmin ac- 
tivity in the elute was assayed using a chromogenic substrate, S-2251  (Lot- 
tenberg et al.,  1981). 
Results 
We determined whether Lp(a) would interfere with the con- 
version of LTGF-/~ to TGF-/~ in our coculture system because 
of the apparent plasmin dependence of LTGF-~ activation 
(Sato and Rifldn, 1989;  Sato et al., 1990) and the reports that 
Lp(a) competes with plasminogen/plasmin binding (Miles et 
al.,  1989; Hajjar et al.,  1989). This first required quantita- 
tion of the minimal amount of plasminogen necessary for ac- 
tivation of LTGF-/~ to conserve Lp(a).  Therefore,  BAECs 
and BSMCs were trypsinized and cocultured for 2 h in me- 
dium  containing  10%  plasminogen-depleted CS  reconsti- 
tuted with known amounts of purified human plasminogen. 
The cultures were washed with PBS and incubated in aMEM- 
BSA for an additional 6 h to produce CM. The CM was then 
tested for TGF-/~ activity in the BAEC wound migration as- 
say (Fig. 1). While the number of cells that migrated >125/~m 
was similar when either fresh medium or CM from cocul- 
tures without plasminogen were tested, the number of mi- 
grating cells decreased as increasing amounts of plasminogen 
were added to the serum used for the initial 2-h incubation. 
Inhibition of BAEC migration was abrogated by neutralizing 
antibodies to TGF-/~ demonstrating that the inhibition was 
due to the activation of LTGF-~. Maximal suppression of 
migration was achieved at a plasminogen concentration of 
55 nM (5/zg/mi).  This corresponds to '~50% of the plas- 
minogen concentration found in 10% CS (Summaria et al., 
1973).  Similar results were obtained when cells were in- 
cubated in a  medium containing  10%  mixtures of normal 
CS and plasminogen-depleted CS at various ratios with the 
maximal suppression obtained with a  1:1 mixture (data not 
shown). 
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Figure 1. Plasminogen dose dependency for LTOF-/~ activation as 
measured by suppression of BAEC migration.  CM was prepared 
from cultures of BAECs/BSMCs incubated in medium containing 
serum reconstituted  with  increasing  plasminogen  concentrations 
as described  in Materials  and Methods.  The CM was added to 
wounded BAEC monolayers, and cell migration was quantitated as 
described.  The number of ceils that had migrated >125 #M was 
expressed as a percent of control using fresh medium. The number 
of cells that had moved >125 #m in the control was 42.  (o) CM 
containing increasing amounts of plasminogen.  (e) CM prepared 
in  the  presence  of  110  nM  plasminogen  and  incubated  with 
wounded BAECs  in the  presence  of neutralizing  antibodies  (10 
ttg/ml) to TGF-/~. 
To test the effect of Lp(a) on LTGF-/~ activation in cocul- 
tures, the cells were exposed to a fixed concentration of plas- 
minogen (55  nM) plus  increasing concentrations of Lp(a) 
during the initial 2-h incubation.  As illustrated in Fig. 2, a 
fivefold molar excess of Lp(a) to plasminogen alleviated the 
normally observed suppression of BAEC migration with CM. 
The effect was dose dependent and a significant abrogation 
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Figure 2.  Inhibition  of LTGF-/~ activation by Lp(a).  Lp(a)  was 
added to cocultures of BAECs/BSMCs at the indicated concentra- 
tions together with 55 nM plasminogen as described.  CM was pre- 
pared and tested for TGF-~ activity in wound assays using BAEC 
migration as before. Cell migration was expressed as a percent of 
control using fresh medium.  The number of cells that had moved 
>125 ttm in the control was 30. The molar excess of Lp(a) to plas- 
minogen is also illustrated on the abscissa. 
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served at a 2.5 M excess of Lp(a) to plasminogen.  Similar 
results to those illustrated in Figs.  1 and 2  were obtained 
using PA activity levels in BAEC to quantitate the generation 
of TGF-B rather than the BAEC migration (data not shown). 
This assay relies upon the observation that TGF-B suppresses 
PA activity in EC (Saksela et al.,  1987) and detects TGF-B 
in the 10-60 pg/ml range (Dennis and Rifkin,  1991).  The 
amount  of TGF-B present  in  the  coculture CM  (Fig.  1) 
ranged from 35  +  6 pg/mi at the highest plasminogen con- 
centration (110 nM),  18 +  3 pg/ml at 55 nM plasminogen, 
and 8  +  1 pg/ml at 13.7 nM plasminogen. 
We assumed that the inhibitory effect of Lp(a) on the acti- 
vation of LTBF-B in cocultures could be ascribed to competi- 
tion between Lp(a) and plasminogen for binding. Therefore, 
under conditions of Lp(a) excess,  plasminogen no longer 
bound to BAECs/BSMCs thereby blocking the plasmin for- 
mation required for activation of LTGF-B. As a test of this 
hypothesis,  we measured the effect of LDL in cocultures 
since it is similar to Lp(a) but lacks the plasminogen homo- 
logue apolipoprotein (a) (Scanu and Fless, 1990). Therefore, 
LDL would be expected not to affect LTGF-/$ activation. As 
shown in Fig.  3 A,  addition of LDL and plasminogen to 
cocultures failed to abolish the activation of LTGF-B, while 
inclusion of Lp(a) did (compare samples 3 and 4 with 2). 
This result suggests that, indeed, it is the apolipoprotein (a) 
component of Lp(a)  that  is  important  for the  inhibitory 
effect. LDL had little effect when added during the 6-h incu- 
bation (Fig.  3 A,  sample 6).  Interestingly, the addition of 
Lp(a) during the 6-h incubation period had little effect as 
compared with its simultaneous addition with plasminogen 
during the initial 2-h incubation period (Fig. 3 A, compare 
samples 3 and 5). We presumed the reason for this difference 
was  that  Lp(a)  is  ineffective in  removing  membrane-  or 
matrix-bound plasminogen.  This was  supported by the ex- 
periment illustrated in Fig. 3 B in which plasminogen was 
added during the second incubation period rather than the 
first.  This resulted in the same suppression of BAEC mi- 
gration as plasminogen addition during the 2-h incubation 
period (Fig. 3 B, samples 2 and 4). CM collected 45 rain af- 
ter  initiating  the  incubation  with  plasminogen,  however, 
showed only ~28 % of the TGF-B activity produced after 6-h 
incubation (Fig. 3 B, compare samples 3 and 4). Although 
the  simultaneous  addition  and coincubation of Lp(a) and 
plasminogen inhibited the activation of TGF-~ (Fig.  3 B, 
sample 6), the addition of Lp(a) after a 45-min incubation 
of cells with plasminogen did not (sample 5). These results 
suggest that a  maximal amount of plasminogen bound to 
cells within 45 min but only a fraction of the final amount 
of TGF-/$ was generated during this period. Once plasmino- 
gen bound to the ceils, however, Lp(a) could not replace it 
under our experimental conditions and did not affct LTGF-B 
activation during the subsequent 5 h. Therefore, Lp(a) prob- 
ably blocks TGF-/~ activation at the initial step of plasmino- 
gen binding. 
Several control experiments were performed to insure that 
the effect of Lp(a) was not indirect. The addition of Lp(a) 
directly to wounded BAECs did not alter their migration 
(Fig. 4, sample 2), thereby ruling out that the observed effect 
of Lp(a) (sample 5) was simply the result of a stimulation of 
BAEC movement. The addition of 0.6 #M (50 #g/mi) human 
plasmin to Lp(a)-treated and untreated cultures during the 6-h 
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Figure 3.  Characterization of the effect of Lp(a) on activation of 
LTGF-/~. (A) Comparison of the effect of Lp(a) and the effect of 
LDL: CM was prepared from untreated cocultures (sample 2) and 
cocultures treated with Lp(a) (275 nM) (samples 3 and 5) or LDL 
(455 nM) (samples 4 and 6) during the 2-h incubation period (sam- 
pies 3 and 4) or during the 6-h incubation period (samples 5 and 
6).  TGF-/~ generated  in  each  sample was  measured by BAEC 
wound assays using fresh medium.as  a control (sample 1).  (B) 
Comparison of the effect of addition of Lp(a) at the same time or 
after plasminogen: Plasminogen (55 nM) was added to cocultures 
at the time when cells were seeded (sample 2) or when the serum- 
containing medium was changed to aMEM-BSA (samples 3-6). 
CM was collected after 6 h, as usual, except the CM of sample 3 
was collected after 45 min. Lp(a) (275 nM) was added with plas- 
minogen either simultaneously (sample 6) or after a 45-min incu- 
bation of  cells with plasminogen and washing the cell surface twice 
with PBS followed by a 5-h incubation (sample 5). Each CM was 
tested for its TGF-/~ activity in BAEC wound assays using 4:1 mix- 
ture of BAEC CM and BSMC CM as a control (sample 1). The 
number of cells that had moved >125 #m in the controls of A and 
B were 50 and 59, respectively. 
incubation period resulted in the production of CM  with 
equivalent ability to suppress BAEC migration (Fig. 4, sam- 
ples 4 and 6). Thus the Lp(a)-mediated block of TGF-/3 for- 
marion observed (Fig. 4, sample 5) was eliminated by this 
treatment. This result suggested that Lp(a) did not inhibit 
plasmin activation of soluble LTGF-/3. Acid-treated CM ob- 
tained from Lp(a)-treated cells contained migration inhibi- 
tory (TGF-/3) activity (Fig. 4, sample 7) indicating that Lp(a) 
did not block LTGF-/3 secretion. The induction of PAI-1 in 
cocultures has been previously shown to result in the inhibi- 
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Figure 4.  Specificity of Lp(a)  inhibition of LTGF-/~ activation. 
Wound assays of BAEC migration were performed using medium 
prepared under the conditions indicated. Sample 1, control medium 
which was a mixture of BAEC and BSMC CM (4:1). Sample 2, 
Lp(a) (69 riM) added to control CM. Sample 3, CM prepared from 
cocultures of BAECs and BSMCs exposed to serum containing 
plasminogen (55 nM) during the 2-h incubation period. Sample 4, 
CM prepared from cocultures of BAECs and BSMCs as in sample 
3 except that plasmin (0.6 #M) was added during the 6-h incubation. 
Sample 5, CM prepared as in sample 3 except that Lp(a) (275 nM) 
was also present during the initial 2-h incubation. Sample 6, CM 
prepared as described for sample 5 except that plasmin (0.6 #M) 
was included during the 6-h incubation. Sample 7, CM prepared 
as described for sample 5 was acidified (pH 2.0, 1 h) before being 
tested in the migration assay. Sample 8, CM prepared as described 
for sample 5 except that c~ PAI-1 IgG (400 #g/ml) was included dur- 
ing the 6-h incubation. Sample 9, CM prepared as described for 
sample 5 except that nonimmune (NI) IgG (400/~g/ml)  was in- 
cluded during the 6-h incubation. The total number of  cells that had 
moved >125/zm in the control sample was 45. 
l 
I 
tion of  LTGF-B  conversion to TGF-/3 (Sato et ai., 1990) since 
PA is required for the activation of plasminogen. It has re- 
cently been reported that Lp(a) stimulates HUVECs to syn- 
thesize and release PAI-1 (Etingen et al.,  1991).  Therefore, 
it was possible that exposure of cells to Lp(a) induced PAI-1 
which prevented the activation of LTGF-/3. However, the ad- 
dition of neutralizing antibodies to PAI-1 to the cocultures 
during the 6-h incubation period did not diminish the effect 
of Lp(a) (Fig. 4, compare samples 8 and 9). In addition to 
these results,  other experiments (data not shown) demon- 
strated that Lp(a) did not block (a) the inhibition of BAEC 
migration observed upon addition of exogenous TGF-/3, (b) 
the artificial activation of LTGF-/3 in CM by acid treatment, 
nor (c) cellular PA activity in cocultures during the prepara- 
tion of CM. 
These results strongly suggest that competitive inhibition 
of plasminogen binding to cells by Lp(a) was responsible for 
the observed inhibition of LTGF-/~ activation. Indeed, in the 
presence of Lp(a), the amount of membrane bound plasmin 
that could be recovered from cultures was reduced by 98 % 
(Fig. 5). 
Since it is SMCs that migrate within atherosclerotic regions 
(Ross, 1986), we determined whether BSMC migration was 
inhibited by coculture CM and whether this was prevented 
by the inclusion of Lp(a) in the medium during the initial 2-h 
incubation (Fig. 6). The suppression of BSMC migration by 
I  Homotyplo 
Culture 
2  Heterotyplo 
CuHure 
3  Het.÷Lp(8) 
4  Het.÷LOL 
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Amount  of  Membrane  Bound  Plasmin  (ng/dlsh) 
Figure 5.  Recovery of membrane bound plasmin activity. After 
BAECs and/or BSMCs were incubated for 2 h in a medium contain- 
ing 10 % plasminogen-depleted CS supplemented with 55 nM plas- 
minogen with or without Lp(a) and LDL as before, plasmin was 
eluted from the surface of the culture and its activity measured as 
described. Sample 1, mixture of BAEC and BSMC eluates (4:1). 
Sample 2, eluate from cocultures. Sample 3, eluate from cocultures 
treated  with  275  nM  Lp(a).  Sample 4,  eluate  from cocultures 
treated with 455 nM LDL. 
I  Control 
2  CM 
CM 
3  +(;TGFfl  Ig( 
CM 
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Figure 6.  Effect of Lp(a) on suppression of BSMC migration by 
coculture CM. BSMC wound assays were performed as described 
in Materials and Methods testing the following additions: sample 
1, control CM defined as in Fig. 3 B; sample 2, coculture CM; sam- 
ple 3, coculture CM supplemented with c~TGF-/3  IgG (10/zg/ml); 
sample 4, coculture CM supplemented with nonimmune (NI) IgG 
(10 #g/ml); sample 5, CM from cocultures treated with Lp(a) (275 
nM); sample 6, CM from cocultures treated with LDL (455 nM); 
sample 7, control CM supplemented with Lp(a) (69 nM). The num- 
ber of cells that had moved >125/zm in the control was 56. 
CM (Fig. 6, sample 2) was neutralized by TGF-/3 antibodies 
(sample 3), and was abolished by the simultaneous addition 
of Lp(a) and plasminogen to cocultures (sample 5). The ad- 
dition of LDL had no effect on the generation of inhibitory 
activity (Fig. 6, sample 6). Lp(a) did not interfere with basal 
BSMC migration (Fig. 6, sample 7). Furthermore, a similar 
result analyzing BAEC migration was obtained using CM 
obtained from cocultures of HUVECs and HFFs as a source 
of CM (data not shown) indicating that human as well as bo- 
vine heterotypic cocultures can generate TGF-/3. 
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The present study characterizes the inhibition by Lp(a) of  the 
activation of L'I'GF-/3 normally observed  in cocultures  of 
ECs  and  SMCs.  Using  plasminogen-depleted  serum,  we 
demonstrated that plasminogen is required for the activation 
of LTGF-/~. Next, we showed that Lp(a) inhibits the activa- 
tion of  LTGF-~ in BAEC/BSMC cocultures without affecting 
the activity  of TGF-~, the plasmin-mediated  activation of 
LTGF-/3, the release of  LTGF-~, the cellular PA activity, or the 
basal migration of BAECs and/or BSMCs. Furthermore,  we 
demonstrated  that Lp(a) inhibited plasminogen binding to 
BAEC/BSMC cocultures,  indicating that the inhibition  of 
LTGF-# activation by Lp(a) probably occurred at the step of 
plasminogen binding. The concentration of  Lp(a) required for 
complete inhibition of LTGF-/~ activation is consistent with 
results reported by Miles et al. (1989) describing the compe- 
tition by Lp(a) with plasminogen binding to HUVECs. 
When the migration  of BSMCs rather than BAECs was 
measured using different CM, a similar inhibitory effect on 
cell migration was observed. The inhibitor (TGF-/5) produced 
in cocultures was absent when the CM was produced in the 
presence of Lp(a). We also demonstrated that cocultures of 
human cells activated LTGF-/~ and that this activation was 
also blocked by the inclusion of Lp(a). 
Interestingly, the inhibitory effect of Lp(a) on LTGF-/3  ac- 
tivation was apparent only when Lp(a) and plasminogen were 
added simultaneously. Once plasminogen had bound to the 
cell surface, Lp(a) was ineffective under short-term condi- 
tions. We do not know the reason for this effect but it is possi- 
ble that this reflects different modes of binding. 
It should be noted that the amount of Lp(a) required to 
block LTGF-/~ is relatively high and exceeds the circulating 
levels found in normal and pathological conditions. The cir- 
culating level of plasminogen is  ml #M, while the Lp(a) 
plasma concentration is i nM-1/zM.  However, recent reports 
indicate that the tissue concentrations of Lp(a) in the intima 
of the arterial wall may be much higher than the circulating 
levels (Rath et al., 1989; Cushing et al., 1989; Niendorf et 
al., 1990). This may reflect Lp(a) binding to glycosamino- 
glycans, fibronectin,  and fibrin fragments.  Therefore,  it is 
possible that Lp(a) concentrations  do exceed plasminogen 
concentrations  within the vessel tissue. 
Numerous  studies have been conducted  in recent  years 
concerning the molecular mechanisms for the regulation of 
cell migration.  Recently it has been shown that bFGF and 
TGF-/$ may be critical in the control of migration of certain 
cells (Mullins and Ritkin, 1990). The regulation of the ex- 
tracellular action of  TGF-/3 is complicated because of  its pro- 
duction in a latent form (Barnard et al., 1990; Roberts and 
Sporn,  1990). We previously reported that the endogenous 
activation of LTGF-/$ by plasmin occurred  in cocultures of 
BAECs and pericytes or BSMCs (Sato and Rifldn, 1989), and 
that this activation may be self-regulating since generation of 
TGF-B stimulates PAId production, which in turn decreases 
subsequent plasmin generation (Sato et al., 1990). Further- 
more, we have proposed that LTBF-B  activation proceeds on 
the cell surface. The evidence for this derives from the obser- 
vation that the interference  of the binding  of mannose-6- 
phosphate  (M6P)-containing  LTGF-B to cell surface M6P/ 
insulin-like growth factor-II receptors inhibits LTGF-/~  acti- 
vation (Dennis and Rifkin, 1991), indicating that surface lo- 
calization  of LTGP-~ is required  for activation.  It is well 
documented  that  the  surface-bound  proteolytic  reactions 
offer several advantages when compared to those in the fluid 
phase (Hajjar et al.  1986; Plow et al., 1986). Thus, it is of 
interest  that all of the components  of LTGF-/3 activation, 
such  as plasminogen,  PA, plasmin,  and M6P/insulin-like 
growth factor-II receptors, and LT(}F-/3 exist on the cell sur- 
face. The findings in the present study stress the importance 
of surface plasminogen binding. It must be noted that Hajjar 
et al. (1986) reported that human plasminogen did not bind 
to BAECs or BSMCs and that the binding of plasminogen 
was species specific. On the other hand, Stephen et al. (1989) 
described that bovine plasminogen was able to bind to hu- 
man fibrosarcoma cells and that there was no apparent spe- 
cies specificity. In our study human plasminogen did bind to 
bovine cells.  We cannot explain this discrepancy between 
our results and those of Hajjar et al. (1986). It must also be 
noted that we have not discriminated between the binding of 
plasminogen to cell membranes or to cell matrix. 
The current studies suggest a new role for Lp(a) in athero- 
genesis. We propose a molecular mechanism for the Lp(a)- 
induced inhibition of LTGF-/5 activation and suggest a rela- 
tionship between the activation  of LTGF-/5  and atherosclerosis. 
We suggest that under normal conditions,  LTGF-B may be 
activated at sites where ECs and SMCs are in contact and 
function to maintain the tissue architecture. Thus, excess tis- 
sue levels of Lp(a) may decrease TGF-/~ production thereby 
reducing the block on SMC migration. This may account for 
the migration  of SMCs from the media to the intima and 
thereby contribute to the generation of atheromas. 
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